For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
The antibodies in this kit recognize VEGF-A (VEGF165 or isoform d), VEGF162, VEGF145 (isoform e) and VEGF121 (isoform f). One of the sandwiching antibodies is a mouse monoclonal, clone 26503. The other sandwiching antibody is a goat polyclonal raised against human recombinant VEGF165.
Formats:
Features:
Vascular endothelial growth factor (VEGF-A or VEGF) is a homodimeric 34-42 kDa heparin-binding glycoprotein specific for endothelial cells. Currently at least eight variants of VEGF generated by alternative splicing of the same gene have been identified. The various isoforms have different heparin- and neuropilin(-1 or -2)-binding properties as well as solubility characteristics reflecting the different functional properties of the VEGF forms. VEGF is believed to play important roles in inflammation and during normal and pathological angiogenesis, a process that is associated with wound healing, embryonic development, and growth and metastasis of solid tumors. Elevated levels of VEGF have been observed in synovial fluids of rheumatoid arthritis patients and sera of cancer patients.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
| Assay Target | VEGF-A |
|---|---|
| Assay Target Class | Protein |
| Automation Compatible | Yes |
| Detection Method | Alpha |
| Experimental Type | In vitro |
| Product Brand Name | AlphaLISA |
| Shipping Condition | Blue Ice |
| Therapeutic Area | Angiogenesis |
| Unit Size | 5,000 assay points |
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.
Orthogonal systems to cell-based assays are a key requirement in EMA/FDA guidelines for potency estimations and require cross-validation with complementary approaches to prove and strengthen the reliability of results.
In this application note published in collaboration with IBR Inc., you will learn:
A variety of chemotherapeutic drugs with different modes of action have been developed and tested as potential therapies for colorectal cancer. Characterizing the effects of potential drugs with different modes of action is a key part of the process.
In this application note you will learn:
Various cytokines are secreted during an active immune response that can have modulatory effects on target cell populations, including interferon gamma (IFN-ɣ), tumor necrosis factor alpha (TNFa) and several interleukins.
In this application note, you will learn how we investigated:
Product brochure for the Alpha Technology, a versatile, no wash, homogeneous assay technology that's suitable for a broad range of applications.
For the detection of three biomarkers in complex sample matrices, the AlphaLISA and Electrochemiluminescent (ECL) assay technologies were shown to have similar: Assay windows (linear dynamic range), Lower and upper detection limit, Intra-and inter-assay precision (lower % CV) The advantages of using AlphaLISA over ECL are: Shorter total assay duration No wash steps No shaking Lower sample volume requirement for equivalent performance Less expensive instrument and plates required
Biomarker levels were measured directly in CulturPlates-96 and-384 in a simple, fast, all-in-one-well AlphaLISA assay format. The elimination of transfer and wash steps simplifies cellular assays, reduces variability and significantly reduces hands-on time and costs associated with consumables. Integral plasma membrane (EGFR) and secreted solubleproteins (TNFa, IL1ß, IL6, IL8) were successfully determined, on adherent or suspension cells, using the standard AlphaLISA Immunoassay buffer.
The AlphaLISA® assay is a homogeneous immunoassay alternative to classical ELISA. AlphaLISA assays were originally utilized to detect analytesin cell cultures upernatants or serum/plasma samples.
AlphaPlate-1536, Light gray, untreated, Case of 50
List Price : USD1290.0
AlphaPlate-384, Light gray, untreated, Case of 50
List Price : USD567.0
OptiPlate-384, White Opaque 384-well Microplate, Case 50
List Price : USD307.0
